About US
Contact us
-
ASCO: BMS pitches Breyanzi as the first CAR-T for CLL. But will a single-arm trial persuade the FDA?CAR-T therapies havebeen around for six years, but it was only in January that Bristol Myers Squibbunveiledthe first positive readout for such a personalized immunotherapy in chronic lymphocytic leuk2023/5/19
-
Johnson & Johnson cites rebates and discounts for drug price increasesWhy do companies jack up their drug prices each year in U.S.? In recent years, some drugmakers have tried to answer this question with annual statements dressed up as “transparency” reports.2023/5/18
-
Indivior's Opvee crosses FDA finish line, adding new overdose rescue option amid raging opioid epidemicJust two months after Emergent BioSolutions made history by winning the FDA’s blessing to sell its opioid reversal medicine over the counter, a new treatment option has arrived in Indivior'sOpvee.2023/5/16
-
FDA clears Braeburn's long-acting Brixadi to treat opioid use disorderAs the United States' opioid epidemic rages on, health officials are busy looking for ways to help with the response. Now, right on the heels of the FDA's approval for a new overdose resc2023/5/16
-
Eli Lilly damages tripled to $184M in Medicaid rebate fraud caseWhen a federal jury last year ordered Eli Lilly to pay $61 million for skimping out on Medicaid rebates, the company vowed to fight the verdict. But instead of the result Lilly wanted, the award has2023/5/11
-
Sandoz taps Evotec in long-term biosimilar development and manufacturing dealAs Novartis’ Sandoz unit prepares to go it alone, the off-patent medicines specialist is buckling up for the biosimilars long haul. Sandoz on Tuesday struck an accord with Just – Evotec B2023/5/11
-
Defense Department backs new study of Idorsia's Quviviq as a treatment for PTSDOf a variety of medications for post-traumatic stress disorder (PTSD), antidepressants are the most commonly used. For many with PTSD, however, these and other treatments aren’t sufficient.2023/5/9
-
Gilead notches trial win in high-stakes HIV patent case against US governmentIt's extremely unusual for the U.S. government to go after a pharmaceutical company for alleged patent infringement, much less take the case to trial. But in the government's case against Gilead Sc2023/5/9
-
BMS, after last year's West Coast purge, lays off 48 in New JerseyWhile smaller biotech outfits have certainly taken the brunt, the layoff deluge of the past year hasn’t spared big pharmas either. Now, after unveiling more than 250 job cuts in San Diego in Septem2023/5/4
-
Lilly exec blasts IRA's 'nonsensical' distinctions as pharma readies legal attacks elsewhereFor many months, thebiopharma industry haslamentedprice-control aspects of the Inflation Reduction Act. Now, Eli Lilly’s R&D chief is openly attacking a controversial clause in the new drug prici2023/5/4